Clinical Trial Update: A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers [Phase 1]

View source ↗

Summary

A phase 1 clinical trial at Memorial Sloan Kettering is evaluating the combination of osimertinib with platinum-based chemotherapy and etoposide for metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Etoposide (Etoposide)
• Osimertinib (osimertinib)
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING